ACRS — Aclaris Therapeutics Share News
0.000.00%
Last trade - 00:00- $628.49m
- $523.07m
- $7.83m
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations
Brief: Aclaris Therapeutics Q4 Net Income USD -19.795 Million Vs. IBES Estimate USD -17.6 Million
Brief: Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052
U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla
U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin
U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge
Aclaris rises as inflammation drug shows promise in early trial
Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows
Brief: Aclaris Therapeutics Q3 Net Income USD -14.614 Million Vs. IBES Estimate USD -15.8 Million
Aclaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Aclaris Therapeutics Q2 Net Income USD -15.429 Million Vs. IBES Estimate USD -16.4 Million
Aclaris Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Aclaris Therapeutics Announces Positive Top-Line Results From Open-Label Phase 2A Trial Of Ati-2138, A Potent And Selective Investigational Inhibitor Of Itk And Jak3 Trial Achieves Primary And Key Secondary Endpoints
Brief: Aclaris Therapeutics Announces Leadership Transition
Brief: Aclaris Therapeutics Initiates Phase 1A/1B Program For Its Novel Bispecific Antibody Ati-052
Brief: Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug In Atopic Dermatitis